US › Healthcare

BioRestorative Therapies Inc (BRTX)

US · Healthcare · Biotechnology

$2.65+4.12%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

$23,170

Revenue YoY

-7.3%

Net profit

$-2.2M

EPS

$6.00

EPS estimate

$3.00

Net margin

-9,298.3%

EPS came in at 6.00 against a street estimate of 3.00 — a beat of 100.0%.

Key statistics

Market cap

$3.5M

Forward P/E

0.0

P/B

1.21

Book value

$2.38

EPS (TTM)

$-21.20

52-week high

$34.60

52-week low

$2.55

50-day MA

$4.73

200-day MA

$9.70

Beta

0.74

Analyst view

Analysts rate BioRestorative Therapies Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $160.00.

Shareholding

Insiders

9.56%

Institutions

13.90%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	3.08%
Geode Capital Management, LLC	2.51%
UBS Group AG	1.12%
Wealth Alliance, LLC	0.45%
Vanguard Fiduciary Trust Co	0.44%
State Street Corp	0.37%
Keystone Financial Group Inc	0.32%
Advisor Group Holdings, Inc.	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioRestorative Therapies Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.